Immix Biopharma's Subsidiary Says Investigational CAR T Therapy Shows 100% Response Rate In Amyloidosis
Portfolio Pulse from Vandana Singh
Immix Biopharma's subsidiary Nexcella announced updated clinical data from its NEXICART-1 study of CAR-T cell therapy NXC-201 for AL amyloidosis, showing a 100% response rate. The therapy was well tolerated and potentially efficacious for advanced, relapsed/refractory AL amyloidosis.
May 22, 2023 | 3:48 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Immix Biopharma's CAR-T cell therapy NXC-201 shows 100% response rate in AL amyloidosis clinical trial, potentially boosting the company's stock.
The positive clinical trial results for Immix Biopharma's NXC-201 therapy indicate a potential breakthrough in treating AL amyloidosis. This could lead to increased investor interest and a rise in the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
NEUTRAL IMPACT
Immix Biopharma announced early interim data from the IMMINENT-01 Phase 1b/2a trial combining IMX-110 with BeiGene's tislelizumab for advanced solid tumors.
The early interim data from the IMMINENT-01 trial is not directly related to the NXC-201 therapy for AL amyloidosis. However, it shows Immix Biopharma's ongoing collaboration with BeiGene, which could have potential implications for both companies in the future.
CONFIDENCE 70
IMPORTANCE 40
RELEVANCE 25
NEUTRAL IMPACT
Immix Biopharma announced early interim data from the IMMINENT-01 Phase 1b/2a trial combining IMX-110 with Novartis' tislelizumab for advanced solid tumors.
The early interim data from the IMMINENT-01 trial is not directly related to the NXC-201 therapy for AL amyloidosis. However, it shows Immix Biopharma's ongoing collaboration with Novartis, which could have potential implications for both companies in the future.
CONFIDENCE 70
IMPORTANCE 40
RELEVANCE 25
NEGATIVE IMPACT
Immix Biopharma's NXC-201 showed positive results in patients relapsed/refractory to Johnson & Johnson's Darzalex-based regimens, potentially impacting JNJ's market share.
The positive results of Immix Biopharma's NXC-201 in patients who were relapsed/refractory to Johnson & Johnson's Darzalex-based regimens could indicate a potential competitor for JNJ's product. This may lead to a decrease in market share for JNJ's Darzalex.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 50